Massive Bio, GLOW partner to widen clinical trial access

Massive Bio and Global Leadership in Oncology & Wellness are teaming up to bring trial matching and navigation support to patients and caregivers in GLOW’s community. The partnership is aimed at helping families find clinical trial options earlier and make more informed cancer care decisions.

Why it matters: - The partnership could help more cancer patients and caregivers learn about clinical trial options earlier in their care journey. - Better trial awareness can improve access to precision medicine and may expand participation in research that reflects patient needs. - GLOW’s trusted community programs and Massive Bio’s trial matching tools are designed to close gaps in awareness, access and representation.

What happened: - Massive Bio announced a partnership with Global Leadership in Oncology & Wellness, a 501(c)(3) nonprofit focused on connecting patients, caregivers and the scientific community. - The collaboration will connect GLOW’s community with information about clinical trial options and guidance to act on that information. - The announcement was made Nov. 2, 2026, in Boca Raton, Florida.

The details: - GLOW’s education and advocacy programs will be paired with Massive Bio’s clinical trial matching and navigation platform. - Massive Bio’s platform uses patient-consented multimodal data and clinical intelligence to identify patients and support trial enrollment. - GLOW’s programs include mentorship, peer support, educational workshops, nurse navigation and access to clinical trials. - Massive Bio said the partnership will make its trial matching and navigation support available to families that rely on GLOW’s programs. - GLOW said the effort is intended to help patients make informed decisions about cancer care, including when clinical trials are appropriate. - Massive Bio operates in 17 countries and serves pharmaceutical and biotechnology companies, CROs, providers and researchers. - Massive Bio said it is powered by RNex (Reticulum Nexus™) and is an OpenAI Select Partner, a DiMe Seal recipient, a founding member of CancerX and a participant in the White House Cancer Moonshot initiative. - GLOW said it works to promote health equity, increase clinical trial awareness and strengthen patient and caregiver support. - More information is available in Massive Bio's announcement and on GLOW Oncology's website.

Between the lines: - The partnership reflects a broader push in oncology to pair digital trial-matching tools with human-centered advocacy and navigation. - The companies are betting that trust matters as much as technology when patients are deciding whether to explore a trial. - By working through GLOW, Massive Bio can reach families through an organization they already know.

What's next: - Massive Bio will support GLOW’s community with trial matching and navigation services. - GLOW is expected to continue using education, advocacy and support programs to guide patients from diagnosis through survivorship. - The partnership may create a pathway for more families to identify trials that could fit their treatment options.